Immobilization of HIV-1 TAT peptide on gold nanoparticles: A feasible approach for siRNA delivery.
Apoptosis
/ genetics
Cell Line, Tumor
Cyclin D1
/ genetics
Gene Transfer Techniques
Gold
/ chemistry
HIV-1
/ metabolism
Humans
Immobilization
/ physiology
Metal Nanoparticles
/ chemistry
RNA, Small Interfering
/ administration & dosage
Transfection
/ methods
tat Gene Products, Human Immunodeficiency Virus
/ chemistry
HIV-1 TAT
ROR1 siRNA
cell penetrating peptide
gold nanoparticles
siRNA delivery
Journal
Journal of cellular physiology
ISSN: 1097-4652
Titre abrégé: J Cell Physiol
Pays: United States
ID NLM: 0050222
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
26
11
2018
accepted:
14
06
2019
pubmed:
1
8
2019
medline:
16
12
2020
entrez:
1
8
2019
Statut:
ppublish
Résumé
RNA interference is one of the prosperous approaches for cancer treatment. However, small interfering RNA (siRNA) delivery to cancer cells has been faced with various challenges restricting their clinical application over the decades. Since ROR1 is an onco-embryonic gene overexpressed in many malignancies, suppression of ROR1 by siRNA can potentially fight cancer. Herein, a delivery system for ROR1 siRNA based on HIV-1 TAT peptide-capped gold nanoparticles (GNPs) was developed to treat breast cancer. Besides, we introduced a new feasible method for conjugating the peptide to the nanoparticles. Since the GNPs have high affinity to the sulfur, the findings demonstrated the peptide successfully conjugated to the nanoparticles via Au-S bonds. As positively charged nanoparticles showed high cellular uptake, we could use a low concentration of nanoparticles led to high efficient gene transfection with negligible cytotoxicity that was confirmed by flow cytometry, confocal microscopy, gel retardation, and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Following transfection, downregulation of ROR1 and its targeted gene, CCND1, induced apoptosis in cancer cells. In conclusion, the reported capped GNPs could be potentially utilized for delivering negatively charged therapeutic agents in particular genes.
Substances chimiques
RNA, Small Interfering
0
tat Gene Products, Human Immunodeficiency Virus
0
Cyclin D1
136601-57-5
Gold
7440-57-5
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2049-2059Informations de copyright
© 2019 Wiley Periodicals, Inc.